ExCellThera is an advanced clinical stage biotechnology company focused on delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use.
The Situation: Stem cell transplantation (usually from bone marrow, peripheral blood or umbilical cord blood), also known as Hematopoietic Stem Cell Transplantation or HSCT is a medical procedure most often performed on patients with cancers of the blood or bone marrow.
The Problem: HSCT is associated with a high treatment-related mortality (TRM) in the recipient, relapse and other major complications, including graft-vs-host-disease (GvHD), all of which limits the use of HSCT in life-threatening situations.
The Solution: ExCellThera’s proprietary lead solution, ECT-001, uses the molecule UM171 and an optimized expansion culture system to expand stem and immune cells:
- greater than 35 times;
- in shorter periods (7 days: 2-3x faster than competitors);
- with reduced volumes needed for transplant (600 mL vs. 10-30 L for competitors);
- at lesser cost; and
- based on Phase I/II findings, significantly reduced TRM, relapse and GvHD.